Pregnancy/Implantation Rates Using a Day 3 Score Versus Graduated Embryo Score Plus a Biochemical Marker (sHLA-G)

This study has been completed.
Sponsor:
Information provided by:
University of Stellenbosch
ClinicalTrials.gov Identifier:
NCT00680238
First received: May 15, 2008
Last updated: May 19, 2008
Last verified: May 2008
  Purpose

Objective: To compare pregnancy rates and implantation rates when embryos are selected based on a single Day 3 (D.3) score vs. a GES score plus sHLA-G expression.


Condition Intervention
Infertility
Drug: Human derived FSH

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Official Title: Pregnancy and Implantation Rates When Embryos Are Selected Based on a Single Day 3 Score (Day 3)vs Graduated Embryo Score(GES) Plus Soluble Human Leukocyte Antigen-G Expression.

Resource links provided by NLM:


Further study details as provided by University of Stellenbosch:

Primary Outcome Measures:
  • Pregnancy and implantation rates [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Miscarriage rates [ Time Frame: 9 months ] [ Designated as safety issue: No ]
  • Miscarriage rates [ Time Frame: 9-11 day until βhCG ] [ Designated as safety issue: No ]

Enrollment: 214
Study Start Date: June 2004
Study Completion Date: June 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: A
Embryo selection for transfer based on a Day 3 score only.
Drug: Human derived FSH
Customized for each patient
Other Name: Bravelle
Active Comparator: B
Embryos for transfer by first selecting any embryos that had a positive sHLA-G expression of OD = 190 ±6 and correlating such with the highest GES score available.
Drug: Human derived FSH
Customized for each patient
Other Name: Bravelle

Detailed Description:

Comparing pregnancy rates and implantation rates when embryos are selected using the most common criteria for embryo selection on day 3 - the morphology-(number of blastomere, their shape and size and the percentage of fragmentation)vs a graduated embryo score accumulated over 72 hours and the expression of sHLA-G at 44-46 hours post fertilization.

  Eligibility

Ages Eligible for Study:   25 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Self paying ART patients

Exclusion Criteria:

  • Abnormal uterus
  • Specific Immunologic factors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00680238

Sponsors and Collaborators
University of Stellenbosch
Investigators
Study Director: Thinus Kruger, M.D. PhD. University of Stellenbosch
  More Information

No publications provided

Responsible Party: Mr DJ Kotze, Stellenbosch University
ClinicalTrials.gov Identifier: NCT00680238     History of Changes
Other Study ID Numbers: DKotze
Study First Received: May 15, 2008
Last Updated: May 19, 2008
Health Authority: South Africa: National Health Research Ethics Council

Keywords provided by University of Stellenbosch:
Pregnancy
implantation
miscarriage
sHLA-G

Additional relevant MeSH terms:
Infertility
Genital Diseases, Male
Genital Diseases, Female

ClinicalTrials.gov processed this record on August 28, 2014